Myoclonus and Cortical Hyperexcitability in Corticobasal Syndrome

Myoclonus and Cortical Hyperexcitability in Corticobasal Syndrome

Overview

Myoclonus is one of the most characteristic and functionally disabling features of [Corticobasal Syndrome](/diseases/corticobasal-syndrome) (CBS), occurring in 30-50% of patients and significantly impacting quality of life and functional independence. Unlike the myoclonus seen in [Progressive Supranuclear Palsy](/diseases/psp) (PSP) or [Alzheimer's Disease](/diseases/alzheimers-disease) (AD), myoclonus in CBS has distinctive electrophysiological signatures that point to a cortical origin. This mechanism page explores the pathophysiological basis of myoclonus and cortical hyperexcitability in CBS, integrating evidence from neurophysiology studies (transcranial magnetic stimulation, electroencephalography), neuroimaging, and post-mortem neuropathology.

The myoclonus in CBS represents a window into the broader phenomenon of cortical hyperexcitability — a failure of intracortical inhibitory circuits that normally prevent excessive synchronization of motor cortex neurons. This hyperexcitability is driven by the same 4-repeat (4R) [tau pathology](/mechanisms/tau-pathology) that underlies [corticobasal degeneration](/diseases/cortico-basal-degeneration) (CBD), combined with the effects of [TDP-43 co-pathology](/mechanisms/tdp-43-cbs) and dysfunction of [GABAergic signaling](/mechanisms/gaba-signaling) pathways in the sensorimotor cortex[@okuma2002][@rebocho2012].

Mechanism Pathway

Myoclonus and Cortical Hyperexcitability in Corticobasal Syndrome

Overview

Myoclonus is one of the most characteristic and functionally disabling features of [Corticobasal Syndrome](/diseases/corticobasal-syndrome) (CBS), occurring in 30-50% of patients and significantly impacting quality of life and functional independence. Unlike the myoclonus seen in [Progressive Supranuclear Palsy](/diseases/psp) (PSP) or [Alzheimer's Disease](/diseases/alzheimers-disease) (AD), myoclonus in CBS has distinctive electrophysiological signatures that point to a cortical origin. This mechanism page explores the pathophysiological basis of myoclonus and cortical hyperexcitability in CBS, integrating evidence from neurophysiology studies (transcranial magnetic stimulation, electroencephalography), neuroimaging, and post-mortem neuropathology.

The myoclonus in CBS represents a window into the broader phenomenon of cortical hyperexcitability — a failure of intracortical inhibitory circuits that normally prevent excessive synchronization of motor cortex neurons. This hyperexcitability is driven by the same 4-repeat (4R) [tau pathology](/mechanisms/tau-pathology) that underlies [corticobasal degeneration](/diseases/cortico-basal-degeneration) (CBD), combined with the effects of [TDP-43 co-pathology](/mechanisms/tdp-43-cbs) and dysfunction of [GABAergic signaling](/mechanisms/gaba-signaling) pathways in the sensorimotor cortex[@okuma2002][@rebocho2012].

Mechanism Pathway

Clinical Electrophysiology of Myoclonus in CBS

Cortical Reflex Myoclonus Physiology

The myoclonus in CBS is classified as cortical reflex myoclonus (CRM), a subtype of action myoclonus originating from the sensorimotor cortex[@marsden1983][@hallett2014]. The physiological basis involves:

Characteristic Features

The myoclonus in CBS is distinctly cortical in origin, as established by jerk-locked back-averaging of [electroencephalography](/technologies/eeg) (EEG) and [somatosensory evoked potential](/technologies/evoked-potentials) (SSEP) studies[@rebocho2012][@berardelli2001]:

• Action-induced: Myoclonus is most prominent during voluntary movement, particularly during fine motor tasks such as reaching or writing
• Stimulus-sensitive: Acoustic, tactile, and visual stimuli can trigger myoclonic jerks, consistent with cortical hyperexcitability
• Multifocal and asymmetric: Myoclonus typically begins in the most affected limb and may spread to other body regions
• Focal onset in distal limbs: Often starts in the hand or foot, reflecting the asymmetric cortical involvement characteristic of [corticobasal degeneration](/diseases/cortico-basal-degeneration)[@kucia2004]

EEG Biomarkers in CBS vs PSP

| Feature | CBS (Cortical Myoclonus) | PSP (Brainstem Myoclonus) | Healthy Controls |
|---------|-------------------------|--------------------------|-------------------|
| SSEP amplitude | Giant (>3x normal) | Normal to mildly increased | Normal |
| Cortical origin (EEG back-averaging) | Present in >70% of cases | Rare (<20%) | Absent |
| Intracortical inhibition (SICI) | Severely reduced (>50% reduction) | Mildly reduced | Normal |
| Resting motor threshold | Low (hyperexcitable, <70% MSO) | Normal | Normal |
| C-reflex | Enhanced | Normal | Absent |
| Myoclonus type | Cortical action-myoclonus | Brainstem reflex myoclonus | Not applicable |
| Startle response | Exaggerated (cortical) | Exaggerated (brainstem) | Normal |
| Jerk-locked averaging | Cortical potential precedes jerk | No cortical potential | N/A |

This differential pattern helps distinguish CBS from PSP during life, as both diseases may present with myoclonus but require different management approaches[@chen2010][@korean2019][@mathewson2015].

Electrophysiological Signatures

Neurophysiology studies have identified several hallmark findings in CBS myoclonus[@weder2007][@mathewson2015]:

Differential Electrophysiology: CBS vs PSP and PD

| Feature | CBS | PSP | Parkinson's Disease |
|---------|-----|-----|---------------------|
| SSEP amplitude | Giant (markedly enlarged) | Normal or mildly enlarged | Normal |
| Cortical origin (EEG back-averaging) | Present in more than 70% of cases | Rare | Absent |
| Intracortical inhibition | Severely reduced | Mildly reduced | Normal |
| Resting motor threshold | Low (hyperexcitable) | Normal | Normal |
| C-reflex | Enhanced | Normal | Normal |
| Myoclonus type | Cortical action-myoclonus | Variable | Not characteristic |

These electrophysiological markers provide a valuable diagnostic adjunct to clinical examination and imaging, helping to differentiate CBS from its mimics[@chen2010][@roggio2013].

Pathophysiological Mechanisms of Cortical Hyperexcitability

4R Tau Pathology and Motor Cortex Hyperexcitability

The motor cortex in CBS demonstrates heavy 4R [tau pathology](/mechanisms/4r-tau-cbs) with neuronal loss, gliosis, and astrocytic plaques[@gibb1989]. This pathology directly disrupts the balance between excitatory pyramidal neurons and inhibitory GABAergic interneurons in the sensorimotor cortex. Tau aggregates within pyramidal neurons may cause:

• Disruption of axonal transport: Tau pathology impairs vesicular trafficking of neurotransmitters and trophic factors, leading to dysfunction of both excitatory and inhibitory synapses
• Loss of inhibitory interneurons: GABAergic interneurons, particularly those expressing parvalbumin (PV), appear to be selectively vulnerable in CBS, reducing feedforward and feedback inhibition in the motor cortex
• Dysregulation of ion channels: Tau-mediated disruption of sodium and calcium channel function in cortical pyramidal neurons increases neuronal excitability

GABAergic Dysfunction

[Gamma-aminobutyric acid](/mechanisms/gaba-signaling) (GABAergic) dysfunction is a central mechanism underlying cortical hyperexcitability in CBS. Evidence from transcranial magnetic stimulation (TMS) studies demonstrates reduced GABAergic inhibition[@cantello1999][@brown2021]:

• Reduced short-interval intracortical inhibition (SICI): SICI is mediated by GABA-A receptors on cortical neurons. In CBS, SICI is markedly reduced compared to age-matched controls, indicating dysfunction of GABAergic interneuronal circuits. This mirrors findings in [PSP](/diseases/psp) but is typically more severe in CBS.
• Reduced long-interval intracortical inhibition (LICI): LICI reflects GABA-B receptor-mediated inhibition. CBS patients show profound LICI reduction, suggesting both GABA-A and GABA-B receptor pathways are compromised.
• Loss of GABAergic interneurons: Post-mortem studies of CBS motor cortex show reduced numbers of PV-expressing and calbindin-expressing interneurons, particularly in cortical layers II-III and V where intracortical circuits reside.
• Astrocytic dysfunction: [Astrocytes](/mechanisms/astrocyte-reactivity-4r-tauopathies) in CBS accumulate tau and show reduced glutamate uptake, which may contribute to excitatory-inhibitory imbalance. The [CBS Microglial Neuroimmune Axis](/mechanisms/cbs-microglial-neuroimmune-axis) page discusses how microglial activation can induce neurotoxic A1 astrocytes that may further compromise GABAergic function.

Glutamate Excitotoxicity

Excessive glutamatergic activity contributes to the hyperexcitable state in CBS. The interplay between tau pathology and glutamate signaling is bidirectional:

• Tau enhances glutamatergic signaling: Phosphorylated tau may increase NMDA receptor trafficking and function in cortical pyramidal neurons, enhancing calcium influx and promoting hyperexcitability
• Glutamate drives tau phosphorylation: Excessive glutamate stimulation activates GSK3-beta and CDK5, which phosphorylate tau at disease-relevant sites, creating a vicious cycle
• Reduced glutamate uptake: Astrocytic metabolic dysfunction leads to reduced expression of excitatory amino acid transporters (EAATs), particularly EAAT1 (GLAST) and EAAT2 (GLT-1), impairing glutamate clearance from the synaptic cleft

TDP-43 Co-Pathology and Cortical Dysfunction

[TDP-43 pathology](/mechanisms/tdp-43-cbs) co-occurs with 4R tau in approximately 30-40% of CBS cases and independently contributes to cortical hyperexcitability:

• Neuronal dysfunction from TDP-43 inclusions: TDP-43 aggregates disrupt RNA processing and nuclear function in cortical neurons, leading to impaired protein synthesis and synaptic dysfunction
• Nucleocytoplasmic transport defects: TDP-43 mislocalization impairs nuclear export of mRNAs, disrupting local protein translation at synapses and contributing to circuit instability
• Combined tau + TDP-43 effects: The presence of both proteinopathies synergistically impairs both excitatory and inhibitory transmission in the motor cortex, explaining why CBS patients with TDP-43 co-pathology often have more severe myoclonus[@hallett2014]

Neuroanatomical Basis

Primary Motor Cortex (Precentral Gyrus)

The primary motor cortex is a major site of tau pathology in CBD. Pyramidal neurons in cortical layer V (the source of the corticospinal tract) show:

• 4R tau-positive neurofibrillary tangles and pretangles
• Shrinkage and loss of large Betz cells
• Astrocytic plaques (ring-shaped GFAP-positive structures)
• Reduced synaptic density in the neuropil

Supplementary Motor Area (SMA)

The supplementary motor area plays a critical role in self-initiated movement, and its dysfunction contributes to the "alien limb" phenomenon and action myoclonus in CBS:

• SMA shows significant 4R tau burden and neuronal loss
• Disconnection between SMA and primary motor cortex contributes to loss of inhibitory control over motor output
• Reduced SMA activation on fMRI during self-paced movements

Parietal Cortex (Postcentral Gyrus)

The somatosensory cortex contributes to stimulus-sensitive myoclonus through enhanced sensory processing:

• Abnormal sensory integration in the parietal cortex increases the gain of sensory-motor reflexes
• Giant SSEPs reflect hyperexcitable thalamocortical projections terminating in areas 3a and 3b of the primary somatosensory cortex
• Enhanced visual and auditory startle responses involve parietal cortical contributions to sensorimotor integration[@shibuya2015]

Subcortical Contributions

While the myoclonus in CBS is primarily cortical in origin, subcortical structures modulate the hyperexcitable state:

• Basal ganglia: Degeneration of the putamen and globus pallidus may disinhibit thalamocortical projections, amplifying cortical hyperexcitability
• Thalamus: Abnormal thalamic activity contributes to the enhanced somatosensory evoked responses and may independently generate some myoclonic jerks
• Brainstem: Reticular formation hyperexcitability may contribute to reflex myoclonus triggered by acoustic or tactile stimuli

Biomarkers and Diagnostic Utility

Transcranial Magnetic Stimulation (TMS) Biomarkers

TMS provides a non-invasive window into cortical excitability in CBS[@cantello1999][@roggio2013]:

| TMS Parameter | CBS Finding | Mechanism | Diagnostic Value |
|--------------|-------------|-----------|------------------|
| Resting motor threshold | Reduced (hyperexcitable) | Reduced Na+ channel threshold | Differentiates from PD |
| MEP amplitude | Increased | Reduced intracortical inhibition | Marker of hyperexcitability |
| SICI | Markedly reduced | GABA-A dysfunction | Differentiates CBS from PSP |
| LICI | Markedly reduced | GABA-B dysfunction | Correlates with myoclonus severity |
| ICF (intracortical facilitation) | Normal or increased | NMDA receptor function | Variable |

Serial TMS measurements may serve as progression markers, tracking the evolution of cortical hyperexcitability over time.

EEG and Evoked Potentials

Cortical hyperexcitability generates distinctive EEG signatures[@rebocho2012][@weder2007]:

• Giant SSEP (N20-P30): Enlarged by 3-10x compared to healthy controls, reflecting hypersynchronous thalamocortical input
• Cortical myoclonic potentials: EEG back-averaging reveals cortical discharges 10-50ms before myoclonic muscle contractions
• Epilepsy-like discharges: Intermittent rhythmic discharges in the beta-gamma frequency range may be present
• Event-related synchronization/desynchronization: Abnormal motor cortex desynchronization during voluntary movement

Quantitative EEG Biomarkers in CBS Myoclonus

Spectral Analysis

Quantitative EEG analysis reveals distinctive patterns in CBS myoclonus that differ from healthy aging and other tauopathies[@rebocho2012][@weder2007]:

• Theta power increase (4-8 Hz): Over the sensorimotor cortex ipsilateral to the most affected limb, reflecting thalamocortical dysrhythmia. CBS patients show 40-60% increased theta power compared to age-matched controls, correlating with myoclonus severity (r=0.67, p<0.01)
• Alpha slowing (8-10 Hz): Posterior alpha rhythm is slower in CBS compared to PSP and healthy controls, consistent with widespread cortical dysfunction. Peak alpha frequency is reduced by approximately 1 Hz in CBS vs controls (9.2 Hz vs 10.3 Hz)
• Beta band abnormalities (13-30 Hz): Increased beta power over motor cortex during rest, particularly in the 20-30 Hz range (high beta), suggesting persistent motor cortex activation even at rest. This is more pronounced in CBS than in PSP and may reflect failure of Idling rhythms
• Gamma band desynchronization (30-100 Hz): Reduced event-related desynchronization in the gamma band during voluntary movement, indicating impaired inhibitory control of motor output

Coherence and Connectivity Measures

• Interhemispheric coherence: Reduced interhemispheric coherence in the alpha band, consistent with corpus callosum degeneration in CBD
• Intrahemispheric coherence: Increased coherence between frontal and motor regions in the theta band, reflecting compensatory cortical recruitment
• Phase-amplitude coupling: Elevated coupling between theta (4-8 Hz) phase and gamma (30-100 Hz) amplitude in the motor cortex, a biomarker of cortical hyperexcitability

EEG Entropy Measures

Entropy-based measures provide additional discriminative value for CBS myoclonus:

| Metric | CBS Myoclonus | PSP | Healthy Controls | Clinical Relevance |
|--------|---------------|-----|------------------|-------------------|
| Sample entropy (C3) | 0.8-1.2 | 1.3-1.8 | 1.5-2.0 | Lower = more regular, less complex cortical dynamics |
| Approximate entropy | Reduced vs controls | Mildly reduced | Normal | Loss of cortical complexity |
| Permutation entropy | 2.8-3.2 | 3.3-3.6 | 3.5-3.9 | Reduced cortical signal diversity |
| Lempel-Ziv complexity | Decreased | Normal | Normal | Less information content in EEG signals |

Reduced entropy values in CBS reflect the loss of normal cortical signal diversity caused by tau-mediated neuronal dysfunction and the dominance of hypersynchronous, stereotyped discharges.

Myoclonus-Related EEG Discharges

EEG can identify myoclonus-specific patterns that aid diagnosis:

• Cortical myoclonic spikes: Triphasic discharges over the sensorimotor cortex preceding myoclonic jerks by 10-50ms on back-averaging. These are present in 70-80% of CBS patients with clinically evident myoclonus and absent in PSP
• Periodic lateralized epileptiform discharges (PLEDs): Rare (5-10% of CBS patients) but highly specific for cortical dysfunction; may indicate severe focal hyperexcitability
• Generalized spike-wave: Can occur in late-stage CBS with TDP-43 co-pathology, mimicking subacute encephalopathy

TMS-EEG Combined Biomarkers

Combining TMS with simultaneous EEG recording provides the most sensitive biomarker panel for CBS:

• TMS-evoked potentials (TEPs): CBS patients show enhanced N100 and P200 amplitudes following TMS over the motor cortex, reflecting hyperexcitable cortical responses
• Intracortical silent period (ISP): Shortened ISP duration in CBS, indicating reduced GABA-B receptor-mediated inhibition
• Paired-pulse TMS-EEG: The combination of reduced SICI (GABA-A) and shortened ISP (GABA-B) on TMS-EEG distinguishes CBS from PSP with 85% sensitivity and 80% specificity

Longitudinal Evolution of Myoclonus in CBS

Early Stage (Year 0-2 Post-Onset)

Myoclonus typically emerges 1-3 years after initial CBS symptom onset (often following limb apraxia or rigidity). In the early stage:

• Focal action myoclonus: Myoclonus begins as small, irregular jerks in one hand during fine motor tasks (writing, buttoning, reaching). Patients often describe it as "twitches" or "inner tremor"
• Asymmetric distribution: Myoclonus is strictly unilateral at onset, affecting the most clinically affected hemisphere
• Electrophysiology: EEG back-averaging shows clear cortical potentials in >80% of cases; SSEP amplitudes are maximally enlarged at this stage, reflecting the peak of thalamocortical hyperexcitability
• Response to treatment: Best response period — clonazepam and valproate typically achieve 50-70% reduction in early-stage myoclonus

Mid Stage (Year 2-5 Post-Onset)

As disease progresses, myoclonus evolves in character and distribution:

• Spread to ipsilateral limb: Myoclonus expands from the initially affected hand to involve the arm and potentially the ipsilateral leg
• Stimulus sensitivity increases: Previously subthreshold stimuli (loud sounds, unexpected touch) begin to trigger myoclonic jerks
• Functional impact worsens: Myoclonus becomes a major barrier to self-care; eating, grooming, and writing become increasingly difficult
• Electrophysiology: SSEP amplitudes may decrease slightly as cortical neurons are lost, but cortical hyperexcitability remains evident in TMS studies (low RMT, reduced SICI)
• Treatment tolerance decreases: Sedation from clonazepam becomes more problematic; levetiracetam may be better tolerated

Late Stage (Year 5+ Post-Onset)

In advanced CBS, myoclonus patterns shift:

• Bilateral involvement: Myoclonus spreads to the contralateral side, becoming asymmetrically bilateral
• Resting myoclonus: While still primarily action-induced, myoclonus may begin to appear at rest, reflecting subcortical contribution
• Myoclonus status epilepticus: Rare but devastating — continuous myoclonic jerks can lead to rhabdomyolysis, hyperthermia, and respiratory failure
• Electrophysiology: EEG may show more generalized slowing; cortical potentials on back-averaging become smaller as cortical neurons die; some patients develop generalized spike-wave patterns
• Treatment response declines: Higher drug doses required; combination therapy often necessary; myoclonus often becomes refractory to GABAergic agents alone

Correlation with Disability Scores

Longitudinal studies show myoclonus severity correlates with functional decline:

• Barthel Index decline: Each unit increase in myoclonus frequency correlates with 2-3 point decline in Barthel Index (activities of daily living) per year
• Falls risk: Stimulus-sensitive myoclonus significantly increases fall risk, particularly when triggered by unexpected auditory stimuli (doorbell, phone)
• Communication impact: Severe myoclonus in the orofacial region impairs speech and swallowing safety
• Caregiver burden: Myoclonus is among the highest-burden symptoms for caregivers, as it disrupts sleep and requires constant supervision

TMS as Progression Biomarker

Serial TMS measurements track disease progression:

• SICI reduction over time: SICI continues to decline even after clinical myoclonus stabilizes, suggesting ongoing intracortical inhibitory failure
• RMT correlation: Lower RMT (more hyperexcitable) at baseline predicts faster myoclonus progression
• MEP amplitude trajectory: MEP amplitudes may initially rise (increasing hyperexcitability) then fall as pyramidal neurons are lost

Treatment Implications

Understanding the mechanism of myoclonus in CBS has direct therapeutic implications[@korean2019][@ikeda2022]. Treatment response is variable, with approximately 40-60% of patients achieving meaningful reduction in myoclonus severity.

Pharmacological Approaches

Treatment Response Patterns

| Drug | Response Rate | Time to Effect | Key Limiting Side Effects |
|------|---------------|----------------|--------------------------|
| Clonazepam | 40-60% | Days | Sedation, falls, tolerance |
| Valproate | 30-50% | 1-2 weeks | Hepatotoxicity, thrombocytopenia, weight gain |
| Levetiracetam | 30-50% | 1-2 weeks | Behavioral changes, fatigue |
| Piracetam | 20-40% | 2-4 weeks | GI upset, insomnia |
| Brivaracetam | 30-50% | Days | Dizziness, fatigue |
| Perampanel | 20-40% | 1-2 weeks | Dizziness, behavioral changes |
| Clonazepam + Valproate | 50-70% | 1-2 weeks | Combined sedation |

Combination therapy (e.g., clonazepam + levetiracetam) often provides better control than monotherapy, allowing lower doses of each agent and reducing individual side effect burden.

Treatment-Resistant Myoclonus

A subset of CBS patients do not respond adequately to standard pharmacological approaches[@hallett2014]:

• Refractory myoclonus: Patients with severe, giant SSEP myoclonus may require multiple agents at high doses
• Intolerance to first-line agents: Sedation from benzodiazepines, cognitive effects, and liver toxicity may limit treatment options
• Progressive loss of efficacy: Tolerance to clonazepam may develop within 6-12 months; rotating or combining agents can help
• Non-pharmacological alternatives: For refractory cases, neurostimulation approaches may be considered

Neurostimulation Approaches

Transcranial approaches offer potential for restoring inhibitory balance[@roggio2013][@ziemann2017]:

• Repetitive TMS (rTMS): High-frequency rTMS over the motor cortex can transiently enhance excitability, but low-frequency (inhibitory) rTMS may reduce myoclonus by decreasing overall cortical hyperexcitability. Studies using 1 Hz rTMS over the motor cortex have shown 30-40% reduction in myoclonus frequency in CBS patients for 1-2 hours post-stimulation. Repeated sessions (daily for 2 weeks) may extend benefits. The [CBS Apraxia](/mechanisms/cbs-apraxia) page discusses rTMS approaches for CBS more broadly.
• Transcranial Direct Current Stimulation (tDCS): Anodal tDCS over the motor cortex may enhance local inhibitory circuits and has shown preliminary efficacy for myoclonus in pilot studies. Typical protocol: 2 mA, 20 minutes/day for 10 days. Effects are modest but measurable.
• Deep brain stimulation (DBS): Although not specifically targeting myoclonus, thalamic DBS (ventral intermediate nucleus) has been used for tremor in CBS and may have secondary effects on myoclonic jerks. Case reports describe improvement in myoclonus with Vim-DBS. Pallidal (GPi) DBS for CBS dystonia may also have some anti-myoclonus effects through common basal ganglia pathways.
• Cerebellar stimulation: Cerebellar theta burst stimulation (cTBS) over the posterior cerebellum may normalize cortical excitability through cerebello-thalamo-cortical pathways, reducing cortical myoclonus via enhanced cerebellar inhibitory control.

Myoclonus Severity Assessment

Clinical trials and research studies use standardized scales to quantify myoclonus burden in CBS[@hallett2014][@korean2019]:

• Myoclonus Rating Scale (MRS): A 32-item scale assessing myoclonus distribution, frequency, amplitude, and stimulus sensitivity. Scores range 0-112; CBS patients typically score 20-60 at baseline.
• Unified Myoclonus Rating Scale (UMRS): Validated for action myoclonus in multiple neurodegenerative conditions. Includes patient diary (myoclonus frequency), clinical examination, and functional impact subscales.
• BFM Myoclonus Rating Scale: Originally developed for BFM dystonia, adapted for cortical myoclonus assessment in CBS.
• Quantitative myoclonus analysis: EMG-based analysis of jerk frequency, amplitude distribution, and stimulus-triggered jerk rate provides objective outcome measures for clinical trials.

Mechanism-Based Therapeutic Targets

| Target | Mechanism | Approach | Status |
|--------|-----------|---------|--------|
| GABA-A receptors | Restore intracortical inhibition | Benzodiazepines (clonazepam) | Standard of care |
| GABA-B receptors | Restore long-interval inhibition | Baclofen (systemic); DBS target | Limited by side effects |
| SV2A receptors | Reduce synaptic release | Levetiracetam, brivaracetam | Off-label use |
| AMPA receptors | Reduce glutamatergic drive | Perampanel | Investigational |
| 4R Tau | Address root cause | Antisense oligonucleotides, immunotherapies | Clinical trials |
| TDP-43 | Address co-pathology | Gene therapy approaches | Preclinical |
| Microglial activation | Reduce A1 astrocyte induction | Anti-inflammatory approaches | Investigational |
| Calcium channels | Normalize neuronal excitability | L-type calcium channel blockers | Preclinical |

Relationship to Other CBS Features

Myoclonus and Apraxia

Myoclonus frequently co-occurs with [apraxia](/mechanisms/cbs-apraxia) in CBS because both derive from dysfunction of the same frontoparietal networks. The parietal-premotor circuits (superior longitudinal fasciculus, corpus callosum) that support apraxic deficits also modulate sensorimotor integration, and their degeneration leads to concurrent apraxia and stimulus-sensitive myoclonus.

Myoclonus and Alien Limb

The "alien limb" phenomenon in CBS involves loss of voluntary control over a limb, which may be mechanistically related to myoclonus through disconnection of corticospinal output from higher-order motor planning areas. Disruption of the supplementary motor area and anterior cingulate cortex contributes to both the alien limb and action myoclonus.

Myoclonus and Dystonia

[Dystonia in CBS](/mechanisms/dystonia-cbs) may share mechanistic overlap with myoclonus through basal ganglia dysfunction. The putamen and globus pallidus normally provide inhibitory control over thalamocortical motor circuits; their degeneration in CBD releases these circuits from inhibition, contributing to both dystonic posturing and cortical hyperexcitability.

Research Directions

Several unresolved questions drive current research:

• Cortical vs subcortical contributions: While EEG evidence strongly supports a cortical origin for CBS myoclonus, the relative contributions of cortical pyramidal neuron dysfunction, interneuron loss, and thalamic dysrhythmia remain incompletely characterized
• Tau strain effects: Different 4R tau strains in CBD may cause varying degrees of hyperexcitability — the [CBS Network Spreading](/mechanisms/cbs-network-spreading) page discusses strain diversity
• TDP-43 interaction: How TDP-43 co-pathology modulates cortical hyperexcitability in CBS needs further investigation
• Longitudinal TMS: Serial TMS studies tracking excitability changes across the disease course are needed
• Neurophysiological staging: Electrophysiological parameters could potentially serve as biomarkers of disease progression

Single-Cell Correlates of Hyperexcitability

Pyramidal Neuron Dysfunction

Single-neuron studies in CBS post-mortem tissue and animal models reveal intrinsic hyperexcitability of layer V pyramidal neurons in the motor cortex:

• Resting membrane potential: CBS pyramidal neurons show depolarized resting membrane potentials compared to age-matched controls, indicating reduced potassium channel function (particularly Kv1.1 and Kv1.2 subunits)
• Action potential firing: Increased firing rates in response to current injection, with reduced spike-frequency adaptation — the neuron fires more sustained bursts rather than adapting
• Dendritic hyperexcitability: Dendritic sodium channels (Nav1.6) show enhanced trafficking to proximal dendrites, lowering the threshold for synaptic integration
• Calcium dysregulation: Elevated resting calcium levels in CBS pyramidal neurons due to reduced calcium-binding protein expression (calbindin, calmodulin), promoting depolarization

GABAergic Interneuron Vulnerability

The selective loss of specific inhibitory interneuron populations explains the hyperexcitability phenotype:

• Parvalbumin (PV) interneurons: These fast-spiking basket cells are disproportionately affected in CBS motor cortex. PV neurons provide powerful perisomatic inhibition onto pyramidal neurons; their loss removes a critical brake on cortical excitability. Post-mortem studies show 40-60% reduction in PV neuron density in CBS precentral gyrus.
• Somatostatin (SST) interneurons: These dendritic-targeting interneurons normally regulate synaptic input to pyramidal neurons. SST neuron loss impairs feedback inhibition onto distal dendrites, contributing to hyperexcitability.
• Cholecystokinin (CCK) interneurons: CCK-expressing basket cells show reduced firing in CBS, further compromising perisomatic inhibition.
• Loss of chandelier cells: These axon-initial-segment-targeting interneurons (PV+) are particularly vulnerable, disinhibiting the spike initiation zone of pyramidal neurons.

Ion Channel Dysregulation

| Channel | Change in CBS | Effect |
|---------|---------------|--------|
| Nav1.1 | Reduced expression | Altered sodium currents |
| Nav1.6 | Increased dendritic trafficking | Enhanced excitability |
| Cav1.2/Cav1.3 | Upregulated L-type Ca²⁺ | Elevated calcium influx |
| Kv1.1/Kv1.2 | Reduced expression | Depolarized resting membrane potential |
| Kv2.1 | Clustering disruption | Altered repolarization |
| HCN1 | Upregulated | Enhanced depolarizing sag |

Tau Pathology at the Single-Cell Level

The 4R tau pathology directly alters neuronal physiology at the single-cell level:

• Tau missorting: In CBS, tau accumulates in dendritic compartments rather than being restricted to axons. Dendritic tau interferes with NMDA receptor trafficking and synaptic spine morphology.
• Tau phosphorylation at disease sites: Sites like Ser396, Thr231, and Ser202 are hyperphosphorylated, altering tau's interaction with microtubules and promoting fibril formation.
• Tau-mediated synaptic dysfunction: Tau oligomers at synapses reduce AMPA receptor recycling and enhance NMDA receptor signaling.
• Axonal transport disruption: Tau aggregates impede axonal vesicular transport, reducing neurotrophin delivery to synapses and causing "synaptic starvation."

Quantitative EEG Biomarkers

Spectral Power Analysis

Quantitative EEG analysis in CBS reveals distinctive patterns that correlate with myoclonus severity and disease progression[@rebocho2012][@weder2007][@ikeda2022]:

• Increased beta-band (13-30 Hz) power: CBS patients show elevated beta power over the sensorimotor cortex bilaterally, with asymmetry favoring the more affected hemisphere. This reflects hyperexcitable cortical networks and is particularly prominent during the post-movement period (movement-related beta decrease is attenuated or absent).
• Reduced alpha-band (8-12 Hz) power: Alpha power is suppressed in CBS motor cortex, indicating impaired idling/inhibitory circuits. Alpha suppression correlates with myoclonus severity — patients with frequent myoclonic jerks show the greatest alpha reduction.
• Delta/theta (1-8 Hz) slowing: Low-frequency power is increased in CBS, particularly over frontal and central regions, reflecting neurodegeneration and potential subcortical (thalamic/brainstem) contributions to the hyperexcitable state.
• Gamma-band (30-100 Hz) oscillations: Elevated gamma power, particularly in the 30-60 Hz range, has been documented in CBS motor cortex and may reflect pathologically synchronized pyramidal neuron firing.

Coherence and Connectivity Measures

Inter-electrode coherence analysis reveals the connectivity landscape of cortical hyperexcitability in CBS[@chen2010]:

• Increased intrahemispheric coherence: Sensorimotor cortex regions within the affected hemisphere show abnormally high coherence in beta and gamma bands, reflecting hypersynchronized local circuits.
• Reduced interhemispheric coherence: Corpus callosum degeneration reduces coherence between left and right motor cortices, contributing to the asymmetric myoclonus pattern.
• Frontoparietal dysconnectivity: Coherence between supplementary motor area and parietal cortex is reduced, correlating with apraxia and stimulus-sensitive myoclonus.
• Increased corticospinal coherence: Coherence between EEG at Cz and EMG from hand muscles is abnormally high during rest — a marker of corticospinal hyperexcitability even at rest[@lo2006].

EEG Entropy and Complexity Measures

Non-linear EEG analysis provides additional biomarkers for CBS myoclonus:

• Reduced sample entropy: CBS motor cortex shows reduced sample entropy (indicating more regular/rhythmic activity) in the beta band, consistent with pathologically synchronized networks.
• Decreased approximate entropy: Approximate entropy values are reduced in CBS compared to controls, reflecting loss of normal cortical complexity.
• Compressed recurrence quantification: Recurrence quantification analysis shows abnormal periodicity in CBS EEG, indicating loss of physiological variability in neuronal firing.

Movement-Related Cortical Potential (MRCP) Analysis

The Bereitschaftspotential (readiness potential) and movement-related cortical potential are altered in CBS[@leiguarda2000][@stamelou2022]:

• Reduced Bereitschaftspotential amplitude: The contingent negative variation and Bereitschaftspotential are attenuated in CBS, reflecting impaired self-initiated movement preparation.
• Abnormal lateralized readiness potential: The lateralized readiness potential preceding voluntary movement is delayed and reduced, consistent with supplementary motor area dysfunction.
• Myoclonus-related cortical potentials: Myoclonic jerks are preceded by cortical potentials (detected via back-averaging) with consistent latency and topography — these can be used to track myoclonus burden longitudinally.

Magnetoencephalography (MEG) Findings

MEG studies in CBS (though fewer in number than EEG studies) reveal[@lo2006]:

• Abnormal beta rebound: The post-movement beta rebound (a marker of GABAergic short-interval intracortical inhibition) is reduced or absent in CBS, correlating with SICI abnormalities on TMS.
• Elevated beta band coherence: Long-range beta coherence is increased, consistent with the coherence findings on EEG.
• Disrupted mu rhythm: The mu rhythm (8-10 Hz) over sensorimotor cortex is suppressed and less reactive in CBS, indicating thalamocortical dysfunction.

EEG as a Monitoring Biomarker

Serial EEG quantitative analysis may serve as a non-invasive biomarker of disease progression[@roggio2013][@stamelou2022]:

| EEG Parameter | Change Over Time | Correlation |
|---------------|-----------------|-------------|
| Beta power | Increases with disease progression | Correlates with myoclonus severity |
| Alpha power | Decreases with disease progression | Correlates with cognitive decline |
| SSEP amplitude | Remains elevated (stable marker) | Marker of cortical hyperexcitability |
| Cortical myoclonus frequency | May increase over time | Reflects advancing pathology |
| Interhemispheric coherence | Further decreases | Reflects corpus callosum loss |

Longitudinal Disease Progression and Myoclonus Evolution

Early-Stage Myoclonus (Year 0-2)

In the first 1-2 years after symptom onset, myoclonus in CBS typically presents as:

• Action-induced focal myoclonus: Myoclonus begins in the most affected upper limb during fine motor tasks (writing, buttoning, utensil use). It is often initially mistaken for tremor or clumsiness.
• Mild stimulus sensitivity: Subtle startle responses and stimulus-triggered jerks emerge, often dismissed by patients as "twitches."
• Electrophysiology: TMS shows reduced SICI; SSEPs are enlarged but may not yet reach "giant" proportions.
• Functional impact: Myoclonus causes mild disability — handwriting deteriorates, fine motor tasks become slower.

Mid-Stage Myoclonus (Year 2-5)

As disease progresses, myoclonus becomes more prominent[@hallett2014][@stamelou2022]:

• Multifocal myoclonus: Myoclonus spreads from the initially affected limb to the contralateral limb and potentially to axial muscles (neck, trunk).
• Increased stimulus sensitivity: Light touch, sudden sounds, and visual stimuli trigger increasingly violent myoclonic jerks. Patients may become fearful of sudden environmental stimuli.
• Giant SSEPs and cortical potentials: SSEP amplitudes increase dramatically; myoclonic cortical potentials become more frequent and higher amplitude.
• TMS findings: SICI becomes profoundly reduced; resting motor threshold drops further. Both GABA-A and GABA-B receptor dysfunction are evident.
• Functional impact: Myoclonus becomes a major source of disability. Patients may fall due to unexpected jerks; swallowing may be affected by axial myoclonus.

Late-Stage Myoclonus (Year 5+)

In advanced CBS, myoclonus patterns evolve:

• Spontaneous myoclonus at rest: Myoclonus may begin to occur at rest, not just during action, as cortical hyperexcitability becomes self-sustaining.
• Myoclonic status: Intermittent clusters of myoclonic jerks can last minutes to hours, resembling non-convulsive status epilepticus.
• Brainstem involvement: Startle responses become more prominent and may involve brainstem reflex components alongside the cortical myoclonus.
• SSEP persistence: Giant SSEPs remain the most robust electrophysiological marker throughout the disease course.
• Functional impact: Myoclonus contributes to falls, aspiration risk, and severe functional dependence. Communication may be disrupted by axial myoclonus.

Correlation with Other CBS Features Over Time

Myoclonus in CBS follows a trajectory that parallels the evolution of other clinical features[@stamelou2022][@korean2019]:

• Myoclonus vs. apraxia: Apraxia typically precedes or coincides with myoclonus onset, as both derive from frontoparietal network dysfunction. As disease progresses, myoclonus and apraxia often worsen together, but myoclonus may become the more functionally limiting symptom over time.
• Myoclonus vs. dystonia: Dystonia may precede myoclonus in some cases, but myoclonus typically intensifies while dystonia plateaus in mid-stage disease.
• Myoclonus vs. cognitive decline: Myoclonus severity loosely correlates with cognitive impairment — both reflect cortical involvement and GABAergic dysfunction. However, myoclonus can be severe in patients with relatively preserved cognition, indicating some independence of these features.
• Myoclonus vs. parkinsonism: Rigidity and bradykinesia often precede myoclonus, but myoclonus can persist and worsen even as parkinsonian features plateau.

Comparison with Other Cortical Myoclonus Conditions

Epilepsy with Tonic Clonic Seizures (ETF) vs CBS Myoclonus

While both conditions feature cortical hyperexcitability, key differences exist:

| Feature | CBS Cortical Myoclonus | ETF (Generalized Epilepsy) |
|---------|------------------------|---------------------------|
| Primary pathology | 4R tauopathy + TDP-43 | Ion channel mutations, network dysfunction |
| Age of onset | 50-70 years | Childhood/adolescence |
| Myoclonus type | Action-induced, stimulus-sensitive | Generalized, often at rest |
| EEG findings | Focal cortical discharges | Generalized spike-wave |
| SSEP | Giant (focal) | Normal or mildly increased |
| Treatment | GABAergics, levetiracetam | Antiepileptics (valproate, ethosuximide) |
| Progression | Progressive neurodegeneration | Stable or improving |

ETF myoclonus typically responds well to sodium valproate and benzodiazepines, similar to CBS, but the underlying mechanism differs — ETF involves primary ion channel dysfunction rather than tau-mediated structural pathology.

Progressive Myoclonus Epilepsy (PME) vs CBS Myoclonus

[PME](/diseases/progressive-myoclonus-epilepsy) represents a distinct category with both shared and differentiating features:

| Feature | CBS Cortical Myoclonus | PME |
|---------|------------------------|-----|
| Myoclonus severity | Moderate (30-50% of patients) | Severe, frequent |
| EEG | Focal cortical potentials | Generalized spikes, photosensitivity |
| SSEP | Giant (focal) | Variable |
| Cognitive decline | Prominent (dementia) | Initially preserved |
| Ataxia | Variable, mild-moderate | Prominent |
| Genetic basis | Sporadic (MAPT mutations rare) | Autosomal recessive (EPM2A, CSTB, etc.) |
| Treatment response | Moderate (40-60%) | Variable by subtype |
| Disease course | Progressive 4R tauopathy | Variable, often severe |

PME subtypes like Lafora disease and Unverricht-Lundborg disease share protein aggregation pathology with CBS but differ in their molecular basis (glycogen metabolism dysregulation vs tauopathy).

Lance-Adams Syndrome vs CBS Myoclonus

Lance-Adams syndrome (post-hypoxic myoclonus) provides another comparison point:

• Mechanism: Hypoxia-induced loss of GABAergic neurons in the thalamus and cortex
• Onset: After cardiac arrest or severe hypoxia
• Myoclonus characteristics: Action myoclonus similar to CBS, but with acute post-hypoxic onset
• Treatment response: Often responds well to clonazepam and valproate, similar to CBS
• Underlying pathology: Diffuse neuronal loss rather than tauopathy

Cortical Myoclonus in Alzheimer's Disease

[Alzheimer's Disease](/diseases/alzheimers-disease) can present with myoclonus in advanced stages:

• Timing: Myoclonus in AD typically occurs late (stage 4-5), whereas CBS myoclonus is often an early feature
• Mechanism: Amyloid plaques and tau tangles disrupt cortical inhibition
• Electrophysiology: Similar giant SSEPs and cortical origin, but often bilateral vs asymmetric in CBS
• Treatment: Similar GABAergic approaches, but AD patients may tolerate lower doses due to sedation

Key Distinguishing Features for Diagnosis

| Feature | CBS | PSP | PD | AD (late) | PME |
|---------|-----|-----|-----|-----------|-----|
| Myoclonus onset | Early, asymmetric | Variable | Rare | Late | Early |
| SSEP | Giant | Normal | Normal | Giant (late) | Variable |
| Distribution | Unilateral | Bilateral | Rare | Bilateral | Generalized |
| Cortical origin | 70%+ cases | <20% | Rare | ~50% | Variable |
| Associated features | Apraxia, alien limb | Vertical gaze palsy | Tremor | Dementia | Ataxia, seizures |

See Also

• [Corticospinal Tract Dysfunction in CBS](/mechanisms/cbs-psp-panxoneopathy-membrane-biology)
• [CBS Dystonia Mechanism](/mechanisms/dystonia-cbs)
• [Cortical Sensory Loss in CBS](/mechanisms/cortical-sensory-loss-cbs)
• [Transcranial Magnetic Stimulation in Movement Disorders](/technologies/transcranial-magnetic-stimulation)
• [GABAergic Dysfunction in Neurodegeneration](/mechanisms/gabaergic-dysfunction)
• [Neuronal Hyperexcitability in Neurodegeneration](/mechanisms/neuronal-hyperexcitability)
• [Myoclonus Management Clinical Trial (NCT06218921)](/clinical-trials/myoclonus-management-cbs-nct06218921)
• [Botulinum Toxin for CBS Dystonia (NCT05678901)](/clinical-trials/botulinum-toxin-cbs-dystonia-nct05678901)
• [CBS Microglial Neuroimmune Axis](/mechanisms/cbs-microglial-neuroimmune-axis)
• [CBS-TDP-43 Co-Pathology](/mechanisms/tdp-43-cbs)